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Objective: Alcohol septal ablation (ASA) is a therapeutic alternative to surgical myectomy in
patients with hypertrophic obstructive cardiomyopathy (HOCM). However, the anatomical
variability of the septal branch, risk of complete heart block, and late onset ventricular
arrhythmias are limitations to its therapeutic usage. There is recent interest in the use of
radiofrequency catheter ablation (RFCA) as a therapeutic option in HOCM. We aimed to
assess the safety and efﬁcacy of RFCA in the treatment of symptomatic HOCM.
Methods: Seven patients with symptomatic HOCM (mean age 43.7  15.6 years, ﬁve males),
and signiﬁcant left ventricular outﬂow tract (LVOT) gradient despite optimal drug therapy,
underwent ablation of the hypertrophied interventricular septum. These patients had
unfavorable anatomy for ASA. Ablation was performed under 3D electro-anatomical system
guidance using an open irrigated tip catheter. The region of maximal LV septal bulge as seen
on intracardiac echocardiography was targeted. Patients were followed up at 1, 6, and 12
months post-procedure.
Results: The mean baseline LVOT gradient by Doppler echocardiography was 81  14.8 mm
of Hg which reduced to 48.5  22.6 ( p = 0.0004), 49.8  19.3 ( p = 0.0004), and 42.8  26.1 mm of
Hg ( p = 0.05) at 1, 6, and 12 months respectively. Symptoms improved at least by one NYHA
class in all but one patient. One patient developed transient pulmonary edema post-RFA.
There were no other complications.
Conclusion: RFCA of the hypertrophied septum causes sustained reduction in the LVOT
gradient and symptomatic improvement among patients with HOCM. Electroanatomical
mapping helps to perform the procedure safely.
# 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hypertrophic cardiomyopathy is a genetic condition affecting
one in 500 of the general population.1 It is characterized by
hypertrophy of the interventricular septum caused by
mutations in the genes encoding sarcomere or sarcomere-
associated proteins.2 About two-third of the patients
have signiﬁcant left ventricular outﬂow tract obstruction
(LVOTO) at rest (≥30 mmHg) or at physiologic provocation
(≥50 mmHg).2 Outﬂow obstruction causes increased LV
systolic pressure which is responsible for myocardial ische-
mia, mitral regurgitation, and impairment in diastolic and
systolic function leading to pulmonary hypertension and
heart failure.
In the treatment of hypertrophic obstructive cardiomy-
opathy (HOCM), surgical myectomy is widely employed for
symptomatic patients with elevated LV outﬂow gradient
despite optimal medical therapy.2 A non-surgical alternative
to myectomy is alcohol septal ablation (ASA).3–5 It involves
catheter-based alcohol infusion into the septal coronary
arteries which reduces LVOTO by causing a limited infarc-
tion of the hypertrophied septum.6 However, the outcome of
ASA largely depends on the anatomy of the septal arteries
and therefore, the procedure is not a suitable in many
patients.5,7
Radiofrequency catheter ablation (RFCA) is a newer and a
well-established technique in the management of cardiac
arrhythmias.8,9 Recent studies have demonstrated that RFCA
of the hypertrophied septum in patients with HOCM is feasible
and effective in reducing LVOT gradients by the mechanism of
discrete septal hypokinesia.10,11 Patients who are not suitable
candidates for surgical myectomy and ASA can get beneﬁt of
RFCA of hypertrophied septum. However, atrioventricular
blocks and cardiac tamponade are known to occur with this
procedure.10,11 We hypothesized that the effective use of
multimodality imaging can mitigate these complications. We
present here our experience with RFCA in the treatment of
septal hypertrophy in patients with symptomatic HOCM. In
our study, we aimed to assess the immediate and long-term
safety and efﬁcacy of this procedure.
2. Methods
This is a retrospective study done on patients who have
undergone RFCA for septal hypertrophy in HOCM at our
center. Data of patients were retrieved from archived medical
records.
2.1. Patient selection
Patients with HOCM having an LVOT gradient of >50 mmHg at
rest and symptomatic on adequate medical therapy were ﬁrst
considered for surgical myectomy. Those patients who were
unwilling for surgical myectomy or deemed high-risk for
surgery were assessed for the suitability of ASA. RFCA was
employed on patients who were not considered as optimal
candidates for ASA. All patients were taken up for the
procedure after obtaining a written informed consent.2.2. Evaluation for alcohol septal ablation
A selective left coronary angiogram was performed in multiple
views to visualize the ﬁrst, large septal branch of the left
anterior descending coronary artery. After visualizing the ﬁrst
septal branch, a 0.0014 in. guidewire was inserted into the
artery over which a 2.0 mm  10 mm balloon was advanced
and positioned at the proximal part of the artery. Then, one
milliliter of myocardial echo contrast (MEC) was injected
through the lumen of the catheter to assess the supply area of
the septal branch. For a targeted ﬂow, the balloon was ﬁrst
inﬂated and it was ensured that there was no leak of the
contrast agent occurring along the sides of the balloon.
Patients who either had a small ﬁrst septal branch
(<1.5 mm) or in whom contrast spill over was observed in
the cavity of right ventricle were considered unsuitable for
ASA and proceeded with RFCA.
2.3. Radiofrequency catheter ablation technique
Both right femoral arterial and venous access were obtained.
The procedure was done under sedation and local anesthesia
under the guidance of intracardiac echocardiography (ICE) and
3-D mapping system (CARTO-Biosense Webster, Diamond Bar,
California, USA or EnSite-NavX-Endocardial Solutions, St. Jude
Medical, Inc., St. Paul, MN, USA). Anatomical map of the LV was
created with the help of 3-D mapping system. Bundle of His,
left bundle branch (LBB), left anterior and posterior fascicular
Purkinje potentials were tagged to prevent injury to these
structures during the procedure.
A retrograde, trans-aortic approach was used for mapping
and ablation of the LV septum in all patients. Intracavitary LV
pressure was recorded through the lumen (irrigation port) of
the mapping catheter. The LV cavity was divided into three
zones (high pressure zone, transitional, and low pressure
zone) as shown in Fig. 1. Ablation was performed with a
3.5 mm open, irrigated-tip ablation catheter on the septal
surface of the transitional pressure zone at the area of
maximal septal bulge avoiding tagged potentials (Fig. 1).
Catheter location and stable contact with LV septum were also
monitored under real-time ICE images (Fig. 2). Lesions were
delivered for 60–120 s each with a power setting of 30–40 W
and saline irrigation of 30 ml/min (Cool Flow Irrigation Pump,
Biosense Webster, Diamond Bar, California). Patients also
received adjusted doses of heparin to maintain activated
clotting time of 250–300 s throughout the procedure.
While ablating near the areas of tagged potentials, extra
care was taken to keep catheter tip stable and power setting
was titrated down to 25 W. Bipolar electrograms from the
distal tip of the ablation catheter were continuously monitored
during procedure to avoid injury to the conduction system.
The lesion was assumed to be adequate when local bipolar
voltage reduced to 50% from the baseline value at the ablation
site. Baseline and post-procedure LVOT gradients were
measured invasively.
2.4. Follow-up
A comprehensive transthoracic echocardiography (iE33,
Philips Medical System) performed at baseline and at each
Fig. 1 – CARTO-guided 3D anatomical map of LV with three pressure zones and radiofrequency ablation lesions. (A) The three
pressure zones in 3-D CARTO LAO view with their corresponding pressure tracings. Yellow dots indicate the site of
conduction system signals. The insert shows A-H-V signals (Site of left side His bundle). The gray color indicates the area of
normal pressure zone with no difference in gradient observed in the pressure tracing. Pink zone reflects transition zone and
purple, high pressure zone with corresponding pressure tracings. Note that in (B), the RF lesions (red dots) are delivered in
the transition zone, away from the conduction system (yellow dots).
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All parameters were evaluated by two blinded experts.
Echocardiographic LVOT gradients were measured at resting
conditions and with Valsalva maneuver at baseline and at
each follow-up: one, six, and twelve months post-procedure.
Maximum gradients were noted for analysis.
Patients' ECGs were monitored for the development of
any abnormality; speciﬁcally AV conduction abnormality,Fig. 2 – Intracardiac echocardiographic images during radiofrequ
not in proper contact with septum. In this situation radiofrequenc
contact of the catheter tip with the hypertrophied septum.immediately after the procedure until discharge and during
each follow-up.
2.5. Statistical analysis
All data were analyzed using the Statistical Package for Social
Sciences (SPSS; Chicago, IL, USA) program, version 15.
Parametric and nonparametric paired data were analyzedency catheter ablation. (A) Arrow shows that catheter tip is
y lesion delivery may not be effective. (B) Arrow shows firm
















1 month 6 months 12 months
1 42 M Small 25 100 30 30 17 III I
2 36 M Abnormal MEC 29 95 80 72 40 III II
3 62 M Single coronary 17 90 45 48 38 III I
4 62 F Abnormal MEC 16 65 30 35 30 III I
5 31 F Small 34 84 77 70 65 III II
6 21 M Abnormal MEC 22 67 53 66 90 III III
7 52 M Abnormal MEC 13 66 25 28 20 III I
MEC: myocardial echocardiographic contrast; RF: radiofrequency; LVOT: left ventricular outﬂow tract obstruction; RFCA: radiofrequency
catheter ablation.
a Maximum gradient obtained either at rest or with Valsalva maneuver.
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respectively. p-Values <0.05 were considered signiﬁcant.
3. Results
Between April 2011 and August 2013, seven patients under-
went RFCA for HOCM: ﬁve through CARTO guidance and the
remaining two under the guidance of EnSiteNavX. The mean
age of patients was 43.7  15.6 years (range 21–62 years). Five
were males. All patients were symptomatic (Table 1) despite
optimal medical management. Three patients were on
betablocker, two on diltiazem and two on betablocker with
disopyramide. Systemic blood pressure was normal on
tolerable doses of medical therapy. One patient had automatic
implantable cardioverter deﬁbrillator (AICD) implantation
before RFCA for syncopal VT. The mean number of lesions
delivered during RFA was 22.2  7.5.
3.1. LVOT gradients
The baseline mean LVOT gradient was 81  14.8 mmHg. A
sustained and signiﬁcant reduction in LVOT gradient from
baseline was seen in all but one patient at every follow-up
(Fig. 3). The mean LVEF at baseline was 70%  4.3%. There was
no deterioration in LVEF post-procedure.Fig. 3 – LVOT gradient of individual patients at 1-month,
6-month, and 12-month followup.3.2. Symptomatic status
Symptomatic status improved by at least one NYHA class in all
but one patient. The pre- and post-procedure NYHA class of
the individual patients is given in Table 1. One patient who had
severe mitral regurgitation before the procedure continued to
have severe symptoms and high LVOT gradients. This patient
underwent surgical myectomy and mitral valve replacement
six months following RFCA.
3.3. Complications
One patient developed acute pulmonary edema immediately
after the procedure, which resolved with ventilatory support
and intravenous diuretic therapy. None of the patients
developed AV conduction abnormality during or after the
procedure. There were no arrhythmic episodes except for the
one patient with ICD who had two appropriate shocks
delivered during the follow-up period. The same patient
underwent surgical myectomy in the follow-up period.
4. Discussion
Our study demonstrated that RFCA of the hypertrophied
interventricular septum in HOCM results in signiﬁcant and
sustained reduction of the LVOT gradient without compromis-
ing safety. RFCA may be considered as a therapeutic alternative
to the non-surgical ASA approach in the treatment of HOCM.
Until recently, surgical myectomy, ASA, and dual-chamber
pacing were the most commonly discussed non-pharmaco-
logical modalities for the treatment of patients with symp-
tomatic HOCM.12–17 While dual-chamber pacing reduces LVOT
gradient through dyssynchronous contraction of the septum,
surgical myectomy and ASA achieve the effect by physical
reduction in septal mass thickness. Surgical myectomy and
ASA are the most widely employed non-pharmacological
treatment modalities in HOCM currently. The catheter-based
approach of ASA has gained momentum in the recent
years,15,16 but has two major drawbacks: obligatory require-
ment of a suitable septal artery anatomy and high risk of
complete AV block. In view of these, RFCA seems to be a good
alternative that may overcome these issues.
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The concept of endocardial RFCA was ﬁrst demonstrated by
Lawrenz and Kuhn in 2004 on a 45-year-old man with severe
HOCM.18 The authors reported subaortic septal hypokinesia,
enlargement of the LVOT, reduction of the septal thickness,
and an increase in the exercise capacity of the patient as
observed seven days after the procedure. They proposed that
RF ablation produces septal hypokinesis at the treated
segment and this ineffective contraction resulted in decrease
in pressure gradient across the LVOT. Later, the same authors
demonstrated the effectiveness of the procedure on 19
patients with HOCM.10 Their study showed signiﬁcant im-
provement in 6-min walk test, NYHA class, and 62% reduction
from the resting LVOT gradient at 6 months follow-up.
Sreeram et al.11 also showed promising results in their study
on 32 children with HOCM. In our patients too, the decrease in
gradient and also the symptomatic relief sustained until one
year post-procedure.
4.2. Multimodality imaging for prevention of
complications
The development of complete AV block warranting permanent
pacemaker implantation is one drawback with RFCA in HOCM.
Lawrenz and Kuhn18 reported CHB in 21% of patients who
underwent RFCA and Sreeram et al.,11 in 6% patients. There
was no occurrence of AV block in our patient population.
Tagging the left bundle and the fascicles on the 3-D map
helped to avoid lesions at these sites. The power delivered and
the irrigation rates were lowered if RF energy had to be
delivered close to these structures. We believe that these
measures helped us in avoiding injury to the conduction
system.
ICE proved to be a very useful modality during the
procedure. Catheter manipulation in hypertrophied LV with
small cavity may be difﬁcult and is likely to inﬂuence the
result. Real time ICE images helped us to manipulate ablation
catheter and have stable contact at the desired location on the
septum.
We believe that the single most advantage of this method is
controlled delivery of RF and the avoidance of collateral
damage to conduction system. RFCA is safe and effective in
reducing LVOT gradient and results in symptomatic improve-
ment. The only complication that occurred in our study was
the development of acute pulmonary edema immediately
following the procedure in the ﬁrst patient. This was related to
ﬂuid overload due to repeated irrigation during the ablation.
To our knowledge, this study is the only one to demonstrate
sustained beneﬁcial effects (12 months follow-up) after
radiofrequency ablation in an adult population.
5. Conclusion
RFCA is a promising treatment option in HOCM. It allows
signiﬁcant reduction in LVOT gradient and symptomatic relief
in patients who may not be suitable for surgical myectomy
and ASA. Electroanatomical mapping helps to perform the
procedure safely.6. Study limitation
The main limitation of the study is the small population size. A
larger prospective, multicenter study is needed to establish
safety and efﬁcacy.
Key message:
What is already known?
RFCA is effective in the reduction of septal hypertrophy in
symptomatic HOCM, but the major risk of this procedure is
the occurrence of conduction blocks.
What this study adds?
Multimodality imaging and electroanatomic mapping of
the conduction system used in this study help prevent
conduction blocks in RFCA.
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